Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355158 | 0.84 | LMNA (0.51) | TSHRCYP1A2LMNATDP1KDM4E | |
| SCHEMBL9052757 | 0.83 | LMNA (0.41) | TSHRCYP1A2LMNATDP1KDM4E | |
| SCHEMBL6641067 | 0.79 | POLB (0.60) | TSHRCYP1A2LMNAKDM4EALDH1A1 | |
| SCHEMBL12095254 | 0.78 | CYP1A2 (0.41) | CYP1A2LMNATDP1KDM4EALDH1A1 | |
| SCHEMBL6638773 | 0.78 | SMN1; SMN2 (0.65) | TSHRCYP1A2LMNAKDM4EALDH1A1 | |
| SCHEMBL18531914 | 0.77 | LMNA (0.41) | CYP1A2LMNATDP1KDM4EALDH1A1 | |
| SCHEMBL8686002 | 0.74 | CYP1A2 (0.50) | CYP1A2LMNATDP1KDM4EALDH1A1 | |
| SCHEMBL27716808 | 0.74 | CYP1A2 (0.46) | CYP1A2LMNATDP1KDM4EALDH1A1 | |
| SCHEMBL12095217 | 0.73 | EDNRB (0.44) | CYP1A2LMNATDP1KDM4EALDH1A1 | |
| SCHEMBL12095211 | 0.73 | KDM4E (0.45) | CYP1A2LMNATDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238685-B2 | Benzo-fused heterocycles as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-03 | — | — | US | disclosed |
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | ACTELION PHARMACEUTICALS LTD. | 2005-06-09 | — | — | US | disclosed |
| WO-2003013545-A1 | NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124605-A1 | Novel benzo-fused heterocycles as endothelin antagonisits | EDNRA, EDNRB, ECE1 | TSHR 768/4885CYP1A2 600/4885LMNA 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.